PeptideScanner retained ClinicalTrials.gov record NCT03291821 at 2026-11-15T22:02:39.332Z. Its registry update date was 2020-12-29, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT00608062 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-12-24, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT03842202 at 2026-07-30T20:18:37.981Z. Its registry update date was 2020-12-24, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03593200 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-12-22, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT00446082 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-12-21, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT00698464 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-12-21, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT02220348 at 2026-07-30T20:18:37.979Z. Its registry update date was 2020-12-19, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT04659551 at 2026-11-15T21:49:16.513Z. Its registry update date was 2020-12-09, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT03573908 at 2026-07-30T20:18:37.978Z. Its registry update date was 2020-12-01, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT02229227 at 2026-11-16T17:45:42.793Z. Its registry update date was 2020-11-27, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02654977 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-11-24, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT04578496 at 2026-07-30T20:20:00.372Z. Its registry update date was 2020-11-19, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT04178447 at 2026-11-16T01:46:56.290Z. Its registry update date was 2020-11-18, and PeptideScanner's reviewed identity mapping was glepaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04613700 at 2026-11-16T01:34:15.953Z. Its registry update date was 2020-11-05, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT02404376 at 2026-07-30T20:20:00.368Z. Its registry update date was 2020-11-03, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02064582 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-12, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02916433 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-08, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02461771 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-10-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT02503332 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-10-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT01385956 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-09-28, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT02972983 at 2026-11-15T22:01:45.056Z. Its registry update date was 2020-09-22, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT02563353 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-18, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02059213 at 2026-07-30T20:22:36.939Z. Its registry update date was 2020-09-16, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04129255 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-10, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02149875 at 2026-11-16T17:33:14.861Z. Its registry update date was 2020-08-24, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT02775227 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-08-24, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT02706483 at 2026-07-30T20:24:11.156Z. Its registry update date was 2020-08-18, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT02715115 at 2026-11-15T21:57:22.404Z. Its registry update date was 2020-08-14, and PeptideScanner's reviewed identity mapping was trofinetide.
PeptideScanner retained ClinicalTrials.gov record NCT02869893 at 2026-11-16T01:34:15.953Z. Its registry update date was 2020-08-07, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT03663582 at 2026-11-15T21:55:23.600Z. Its registry update date was 2020-08-04, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04208620 at 2026-11-16T01:47:38.899Z. Its registry update date was 2020-07-31, and PeptideScanner's reviewed identity mapping was cotadutide.
PeptideScanner retained ClinicalTrials.gov record NCT01406444 at 2026-11-16T17:35:13.282Z. Its registry update date was 2020-07-17, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT00551343 at 2026-07-30T20:25:27.243Z. Its registry update date was 2020-07-07, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT03617861 at 2026-11-16T01:34:15.953Z. Its registry update date was 2020-06-11, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT04303819 at 2026-07-30T20:26:41.665Z. Its registry update date was 2020-06-11, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02650206 at 2026-07-30T20:26:41.666Z. Its registry update date was 2020-06-09, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04418908 at 2026-11-15T22:02:39.332Z. Its registry update date was 2020-06-05, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT01792804 at 2026-11-15T22:01:45.056Z. Its registry update date was 2020-05-27, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT03770637 at 2026-07-30T20:27:50.524Z. Its registry update date was 2020-05-21, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02737891 at 2026-11-16T17:29:46.323Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was tesofensine.
PeptideScanner retained ClinicalTrials.gov record NCT03286829 at 2026-11-16T17:29:46.323Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was tesofensine.
PeptideScanner retained ClinicalTrials.gov record NCT02788747 at 2026-07-30T20:27:50.521Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was elamipretide.
PeptideScanner retained ClinicalTrials.gov record NCT02640118 at 2026-07-30T20:27:50.520Z. Its registry update date was 2020-05-07, and PeptideScanner's reviewed identity mapping was lixisenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02925923 at 2026-11-15T21:59:29.646Z. Its registry update date was 2020-05-04, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT02918279 at 2026-07-30T20:29:13.572Z. Its registry update date was 2020-04-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02559206 at 2026-07-30T20:29:13.579Z. Its registry update date was 2020-04-24, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT04358016 at 2026-11-15T21:47:40.408Z. Its registry update date was 2020-04-22, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT02961764 at 2026-11-16T17:37:42.807Z. Its registry update date was 2020-04-10, and PeptideScanner's reviewed identity mapping was dalbavancin.
PeptideScanner retained ClinicalTrials.gov record NCT00002633 at 2026-07-30T20:29:13.591Z. Its registry update date was 2020-04-03, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00002864 at 2026-07-30T20:29:13.581Z. Its registry update date was 2020-04-01, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02160808 at 2026-11-16T01:34:15.953Z. Its registry update date was 2020-03-31, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT03984370 at 2026-11-16T01:42:39.027Z. Its registry update date was 2020-03-31, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT00589134 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-03-30, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT03606057 at 2026-11-16T17:46:45.897Z. Its registry update date was 2020-03-03, and PeptideScanner's reviewed identity mapping was efinopegdutide.
PeptideScanner retained ClinicalTrials.gov record NCT04281680 at 2026-07-30T20:32:04.760Z. Its registry update date was 2020-02-24, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT04175665 at 2026-07-30T20:32:04.760Z. Its registry update date was 2020-02-21, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00203021 at 2026-11-16T17:42:50.457Z. Its registry update date was 2020-02-18, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT00657605 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT00659828 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT02351232 at 2026-07-30T20:32:04.755Z. Its registry update date was 2020-02-12, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03283098 at 2026-11-15T22:07:29.454Z. Its registry update date was 2020-02-10, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT03115307 at 2026-11-15T21:49:16.513Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00226967 at 2026-07-30T20:33:20.622Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02196831 at 2026-07-30T20:33:20.623Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT03233438 at 2026-11-16T17:37:42.807Z. Its registry update date was 2020-01-18, and PeptideScanner's reviewed identity mapping was dalbavancin.